Moderna Inc Cash Flow Conversion Efficiency
Moderna Inc cash flow conversion efficiency. Based on the latest financial reports, Moderna Inc (MRNA) has a cash flow conversion efficiency ratio of -0.078x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-526.00 Million) by net assets ($6.76 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Moderna Inc market capitalisation for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of Moderna Inc (2014–2025)
Cash flow conversion efficiency of Moderna Inc from 2014 to 2025. This chart illustrates how Moderna Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Moderna Inc stock quote for real-time trading data and today's change.
Moderna Inc Cash Flow Conversion Ratio Explained
Moderna Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Moderna Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Moderna Inc ranked by their cash flow conversion efficiency. Review Moderna Inc free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
KDDI CORP.UNSP.ADR 4
F:DIP0
|
N/A |
|
Rheinmetall AG
F:RHM
|
0.446x |
|
Baker Hughes Co
NASDAQ:BKR
|
0.067x |
|
ASS.GENERALI ADR 1/2/EO 1
F:ASG0
|
N/A |
|
Devon Energy Corporation
NYSE:DVN
|
0.108x |
|
Alimentation Couchen Tard Inc A
TO:ATD
|
0.080x |
|
PACCAR Inc
NASDAQ:PCAR
|
0.049x |
|
Cathay Financial Holding Co Ltd
TW:2882
|
-0.108x |
Annual Cash Flow Conversion Efficiency for Moderna Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Moderna Inc from 2014 to 2025. Also see Moderna Inc (MRNA) total assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $8.65 Billion | $-1.87 Billion | -0.217x | +21.42% |
| 2024-12-31 | $10.90 Billion | $-3.00 Billion | -0.276x | -22.44% |
| 2023-12-31 | $13.85 Billion | $-3.12 Billion | -0.225x | -186.41% |
| 2022-12-31 | $19.12 Billion | $4.98 Billion | 0.260x | -72.95% |
| 2021-12-31 | $14.14 Billion | $13.62 Billion | 0.963x | +21.66% |
| 2020-12-31 | $2.56 Billion | $2.03 Billion | 0.791x | +302.59% |
| 2019-12-31 | $1.17 Billion | $-458.97 Million | -0.391x | -80.69% |
| 2018-12-31 | $1.53 Billion | $-330.87 Million | -0.216x | +59.21% |
| 2017-12-31 | $625.30 Million | $-331.48 Million | -0.530x | -768.75% |
| 2016-12-31 | $841.85 Million | $66.73 Million | 0.079x | +100.97% |
| 2015-12-31 | $90.19K | $-738.15K | -8.185x | -848.61% |
| 2014-12-31 | $-4.37 Million | $-4.78 Million | 1.093x | -- |
About Moderna Inc
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses incl… Read more